X
Astellas/Seattle Genetics target advanced bladder cancer with enfortumab vedotin
https://pharmaphorum.com/news/astellas-seattle-genetics-target-advanced-bladder-cancer-with-enfortumab-vedotin/
Seattle Genetics
Seattle Genetics and Astellas gain Breakthrough Designation for urothelial cancer treatment
The FDA has granted Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug conjugate (ADC) being developed by Seattle Genetics and Astellas.
Exclusive Speaker Interview from Seattle Genetics for SMi’s ADC conference
Interview from Seattle Genetics
Seattle, Takeda aim for first line Adcetris use
Seattle CEO hopes Adcetris will be standard of care.
Seattle Genetics halts trials of latest ADC after safety warning
Monitoring committee concerned about high death rates.
Seattle Genetics leukaemia trial on hold after 4 deaths
FDA concerned over potential liver toxicity.